Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Medisinsk teknisk forskningssenter, Olav Kyrres gate 9, 7489 Trondheim, Norway.
Support Care Cancer. 2011 Dec;19(12):2005-14. doi: 10.1007/s00520-010-1051-2. Epub 2010 Nov 30.
The purpose of this study is to examine the adequacy of treatment for constipation, nausea, depression and poor sleep and the factors associated with inadequate symptom control in cancer patients receiving opioids.
Patients receiving strong opioids for cancer pain were recruited from 17 centres in 11 European countries. By using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire C30, 1,938 patients reported their symptoms at four-point scales. Health care providers assessed symptoms at corresponding four-point scales and registered use of medications, demographic and disease-related variables. Symptomatic treatment was scored as 1 if not administered during the past 24 h and as 2 if administered. Adequacy of treatment was evaluated by subtracting the patients' symptom score from the treatment score. Negative scores, caused by either no treatment or ineffective treatment of a symptom, were interpreted as inadequate treatment.
Approximately 60% of patients with constipation, depression or poor sleep and 45% of nauseated patients were inadequately treated. Numbers of inadequately treated patients varied between countries. In general, underestimation of symptom intensity by health care providers (p < 0.001), low performance status (p < 0.05) and recent initiation of opioids (p < 0.05) increased the risk of inadequate treatment. The subset of demographic- and disease-related factors associated with inadequate treatment varied between the symptoms investigated.
Inadequate treatment, either no treatment or ineffective treatment, was frequent in cancer patients. There were subgroups of patients at particular risk for inadequate treatment, which might need additional attention from health care providers for achievement of adequate symptom control.
本研究旨在检查接受阿片类药物治疗的癌症患者的便秘、恶心、抑郁和睡眠不佳症状的治疗是否充分,以及与症状控制不充分相关的因素。
从欧洲 11 个国家的 17 个中心招募了接受强阿片类药物治疗癌症疼痛的患者。通过使用欧洲癌症研究与治疗组织核心生活质量问卷 C30,1938 名患者以四点量表报告他们的症状。医疗保健提供者以相应的四点量表评估症状,并记录药物使用、人口统计学和疾病相关变量。如果在过去 24 小时内未给予治疗,则将对症治疗评为 1,如果给予治疗,则将其评为 2。通过从患者的症状评分中减去治疗评分来评估治疗的充分性。由于未治疗或对症状的治疗无效而导致的负分被解释为治疗不足。
大约 60%的便秘、抑郁或睡眠不佳患者和 45%的恶心患者治疗不充分。治疗不足的患者人数在各国之间存在差异。一般来说,医疗保健提供者对症状严重程度的低估(p<0.001)、较低的体能状态(p<0.05)和最近开始使用阿片类药物(p<0.05)增加了治疗不足的风险。与所研究的症状相关的与人口统计学和疾病相关的因素的亚组与治疗不足相关。
在癌症患者中,治疗不足,无论是未治疗还是治疗无效,都很常见。存在特定亚组的患者存在治疗不足的风险,这可能需要医疗保健提供者额外关注,以实现充分的症状控制。